

(6) a Supplemental Information Disclosure Statement (in duplicate), accompanied by the appropriate provision authorizing payment of the required fee;

(7) a revised PTO 1449 form and copies of the references listed therein; and

(8) a Request for Continued Examination with the appropriate fees.

IN THE CLAIMS:

Please amend the claims as follows:

Cancel Claims 25-27 without prejudice.

Amend Claims 5, 6, 16, and 28-30 as follows.

Add new Claim 31.

The pending claims read as follows:

2. (Previously Amended) The method of Claim 28, wherein the needle is selected from the group consisting of microneedles, catheter needles, and injection needles.
3. (Previously Amended) The method of Claim 28, wherein a single needle is inserted.
4. (Previously Amended) The method of Claim 28, wherein multiple needles are inserted.
5. (Currently Amended) The method of ~~any of Claims 25-30~~ 28, 29, or 31, wherein the substance is a liquid delivered by pressure directly on the liquid.
6. (Currently Amended) The method of ~~any of Claims 25-30~~ 28, 29, or 31, wherein a hormone is delivered.
7. (Previously Amended) The method of Claim 6, wherein the hormone is selected from the group consisting of insulin and PTH.
10. (Previously Amended) The method of Claim 28, wherein the needle is about 300 mm to 2 mm long.
11. (Previously Amended) The method of Claim 28, wherein the needle is about 500 mm to 1 mm long.
12. (Previously Amended) The method of Claim 28, wherein the outlet is at a depth of about 250 mm to 2 mm when the needle is inserted.
13. (Previously Amended) The method of Claim 28, wherein the outlet is at a depth of about 750 mm to 1.5 mm when the needle is inserted.

14. (Previously Amended) The method of Claim 28, wherein the outlet has an exposed height of about 0 to 1 mm.

15. (Previously Amended) The method of Claim 28, wherein the outlet has an exposed height of about 0 to 300 mm.

16. (Currently Amended) The method of Claim ~~26~~ 28, wherein the delivery rate or volume is controlled by spacing of multiple needles, needle diameter or number of needles.

25. (Canceled)

26. (Canceled)

27. (Canceled)

28. (Currently Amended) A method for ~~the~~ administration of a substance to a human subject, comprising delivering the substance into ~~the~~ an intradermal compartment of the human subject's skin at a controlled volume and rate via a needle having a length sufficient to penetrate the intradermal space and an outlet at a depth within the intradermal space so that the substance is distributed ~~systemically~~ in the plasma.

29. (Currently Amended) A method for ~~the~~ administration of a substance to a human subject, comprising delivering the substance into ~~the~~ an intradermal compartment of the human subject's skin, so that the substance is distributed systemically and has a pharmacokinetic profile similar to subcutaneous delivery of the substance, but with a higher plasma levels.

30. (Currently Amended) A method for ~~the~~ administration of a substance to a human subject, comprising delivering the substance into ~~the~~ an intradermal compartment of the human subject's skin, so that the substance is distributed systemically and has a pharmacokinetic profile similar to subcutaneous delivery of the substance, but with a faster onset of a detectable plasma levels.

31. (New) A method for the administration of a substance to a human subject, comprising delivering the substance into ~~the~~ an intradermal compartment of the human subject's skin, so that the substance is distributed systemically and has a pharmacokinetic profile similar to subcutaneous delivery of the substance, but with a higher bioavailability.

REMARKS

First and foremost, Applicants would like to thank Examiners Tran, Denion, Hayes, and Casler for their cooperation in organizing an interview with the Applicants on May 14,